Barclays analyst Yihan Li initiated coverage of Zealand Pharma (ZLDPF) with an Overweight rating and DKK 560 price target The firm says the company’s story is intact with long-term upside despite recent competitor pressure and potential amylin setbacks. Current share levels offer an attractive entry point, the analyst tells investors in a research note.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZLDPF:
- Zealand Pharma initiated with an Outperform at BNP Paribas Exane
- Zealand Pharma price target lowered to DKK 850 from DKK 1,050 at Berenberg
- Zealand Pharma announces results from 28-week Phase 1b trial of dapiglutide
- Zealand Pharma appoints Johnson as Chief Development Officer
- Zealand Pharma’s Earnings Call: Growth Amid Challenges